IMMU Overview
Upcoming Projects (IMMU)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IMMU)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (IMMU)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IMMU)
-
PDUFA date set to Jan 18 2019 for Immunomedics' (IMMU) IMMU-132( sacituzumab govitecan) for triple-negative breast cancer patients
Tickers: IMMU, SEGN
Occurred on: Jan 17, 2019 -
Immunomedics (IMMU) to initiate Phase 3 study of IMMU-132 (sacituzumab govitecan) in triple-negative breast cancer in early 2017
Ticker: IMMU
Occurred on: Mar 15, 2017 -
Immunomedics (IMMU) to Complete Phase 3 Pivotal Trial Preparation for IMMU-132 in Metastatic Triple-Negative Breast Cancer in 2H 2016
Ticker: IMMU
Occurred on: Jan 18, 2017 -
Immunomedics (IMMU) Expects Updated Phase 2 Results for IMMU-130 in Metastatic Colorectal Cancer in 1H 2016
Ticker: IMMU
Occurred on: Apr 18, 2016 -
Immunomedics (IMMU) Expects to Complete Phase 3 Trial Design for IMMU-130 in Metastatic Colorectal Cancer in early 2017
Ticker: IMMU
Occurred on: Mar 21, 2016 -
FDA Designates Immunomedics' (IMMU) IMMU-132 a Breakthrough Therapy for Treatment of Triple Negative Breast Cancer (TNBC)
Ticker: IMMU
Occurred on: Feb 05, 2016 -
Immunomedics (IMMU) Reports Interim Phase 2 Data Evaluating IMMU-132 in Triple Negative Breast Cancer (TNBC)
Ticker: IMMU
Occurred on: Feb 04, 2016
Strategic Initiatives (IMMU)
-
Gilead Sciences (GILD) to Acquire Immunomedics (IMMU)
Tickers: GILD, IMMU
Announcement Date: Sep 13, 2020 -
Clovis Oncology (CLVS) and Immunomedics (IMMU) Announce Collaboration in Metastatic Triple-Negative Breast and Urothelial Cancers
Tickers: IMMU, CLVS
Announcement Date: Jun 03, 2018 -
Seattle Genetics (SGEN) and Immunomedics (IMMU) Announce $2B License Deal for IMMU-132 in Triple-Negative Breast Cancer
Tickers: IMMU, SGEN
Announcement Date: Feb 10, 2017
